As birth spacing has demonstrated health benefits for a woman and her children, contraception after childbirth is recognized as an important health issue. The potential risk of pregnancy soon after delivery underscores the importance of initiating postpartum contraception in a timely manner. The contraceptive method initiated in the postpartum period depends upon a number of factors including medical history, anatomic and hormonal factors, patient preference, and whether or not the woman is breastfeeding. When electing a contraceptive method, informed choice is paramount. The availability of long-acting reversible contraceptive methods immediately postpartum provides a strategy to achieve reductions in unintended pregnancy.
Healthy pregnancy spacing reduces neonatal, infant, and maternal morbidity and mortality ( Fig. 1) . 2 After childbirth, the recommended period before attempting the next pregnancy is at least 24 months. 3 Thus, prompt initiation of contraception after childbirth is critical as it reduces the likelihood of unintended pregnancy and improves the health of mothers and babies by lengthening birth intervals. Choice of contraceptive method in the postpartum period is an important and multifactorial decision. The contraceptive method initiated depends upon medical history, anatomic and hormonal factors, patient preference, and whether or not the woman is breastfeeding. Postpartum women have reported that some of the most important qualities in a contraceptive method are: ease of use, the absence of a need for monthly pharmacy trips, long-term protection, and safety during breastfeeding. 4 
Counseling
Contraceptive plans should optimally be initiated as part of prenatal care and counseling, especially as many methods can be provided at the time of delivery or during the hospital stay. The plan should be revisited before hospital discharge and implemented by 3 weeks postpartum. The majority of women have already resumed sexual relations by 6 weeks postpartum, the most common time for routine postpartum visit. 5 In nonbreastfeeding women, ovulation can occur during the fourth postpartum week. As such, some experts advocate for changing the timing of the routine postpartum visit to 3 weeks as this timing would be more effective in preventing postpartum conception.
A systematic review of the research on the effectiveness of postpartum counseling for contraception found that postpartum education results in more utilization of family planning methods and fewer unplanned pregnancies. 6 Antenatal counseling is essential to ensuring informed choice for the immediate postpartum use of long-acting and permanent methods. As women's individual circumstances and opinions may change over time, strategies for counseling both before and after delivery are beneficial.
Thrombosis Risk
Although venous thromboembolism (VTE) is a rare event, the potential for a catastrophic consequence makes it an important consideration. The normal hematologic changes occurring during pregnancy which shift pregnant women's coagulation and fibrinolytic systems toward increased coagulability persist into the postpartum period, thereby elevating the risk of VTE for postpartum women (Fig. 2) . 7, 8 In fact, VTE risk has been reported to be as much as 5 times greater during the postpartum period than during pregnancy. 9 Data from the 1980s had indicated that blood coagulation and fibrinolysis variables affected during pregnancy returned to normal in women by 21 days postpartum. 10 The assumption was that the elevated risk of VTE associated with pregnancy returns to nonpregnant levels by that time.
However, more recent data indicate that the risk of VTE during the first 6 weeks postpartum is significantly higher than previously thought, ranging from FIGURE 2. Likelihood of venous thromboembolism. *Pregnancy data based on actual duration of pregnancy in the reference studies. Based on the model assumption that pregnancy duration is 9 months, the rate is 7 to 27 per 10,000 WY. Source: http://www.fda.gov/Drugs/DrugSafety/ ucm299305. COC indicates combined oral contraceptive. 21.5-to 84-fold greater than in nonpregnant, nonpostpartum reproductive age women. 11 This risk is most pronounced around the time of childbirth, declining rapidly during the first 3 weeks postpartum as coagulation factors return to prepregnancy levels and nearing normal levels by 6 weeks postpartum. 11 These more recent data caused the World Health Organization (WHO) to reevaluate recommendations for initiation of combined hormonal contraceptives during the postpartum period, resulting in a change in recommendation for 21 to 42 days postpartum from category 1 (no restriction on use) to category 2 (advantages generally outweigh risks).
12,13

Resumption of Ovulation in Nonbreastfeeding Women
In nonbreastfeeding women, mean day of first ovulation ranged from 45 to 94 days postpartum in various studies, with the earliest ovulation reported 25 days postdelivery. 14, 15 Half of these women ovulated before the sixth postpartum week, 14, 16 with the majority of women (ranging from two thirds to three fourths in various studies) ovulating before their first menses. 14, 17 Thus, nonbreastfeeding women begin to ovulate about 4 weeks postpartum, and the return of menses cannot be used as an indicator that ovulation has not previously occurred. Effective contraception should therefore be initiated in nonbreastfeeding postpartum women no later than 3 weeks after delivery. 5 For a more complete discussion of the risks and benefits for each method, see the sections below.
Postpartum Contraception for Nonbreastfeeding Women
STERILIZATION
Permanent sterilization can be performed after a vaginal or cesarean delivery.
Postpartum sterilization following vaginal delivery should be performed by minilaparotomy within 48 hours of delivery as delays increase the risk of infection as well as the difficulty because of uterine involution. [18] [19] [20] The modified Pomeroy technique is the most common sterilization procedure performed following childbirth (either vaginal or cesarean birth) in the United States. The United States Collaborative Review of Sterilization study found this method to be highly effective with a 10-year failure rate of <1% (7.5 pregnancies per 1000 procedures). 21 Both mini-laparotomy after vaginal delivery as well as postcesarean sterilization may need to be delayed in the case of complications, such as severe preeclampsia or eclampsia, premature rupture of membranes, preterm delivery, sepsis, fever, severe hemorrhage, uterine rupture, or perforation. 12, 22 Other logistical barriers including lack of valid Medicaid sterilization consent forms or lack of availability of an operating room may also preclude completion of postpartum sterilization. 23 Vasectomy is also an appropriate postpartum choice for couples desiring a permanent method of sterilization. Compared with female sterilization, it is more efficacious, more cost-effective, and has lower rates of complications. 24 Vasectomy is a less preferable method for women undergoing cesarean delivery and for those without a current partner. All methods of permanent sterilization require appropriate counseling and reflection under nonstressful circumstances, preferably before delivery, to ensure that consent is fully informed, 12, 20, 25 especially as the performance of tubal sterilization in the postpartum period is a risk factor for regret. 26, 27 
BARRIER METHODS
Both the male and female condom can be used as soon as coitus is resumed. Other types of barrier methods, such as the diaphragm and cervical cap, require
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fitting which cannot be properly performed until pregnancy-related cervical changes have resolved, generally by 6 weeks postpartum; it is not advisable to use a sponge, cap, or diaphragm while still bleeding due to the increased risk of toxic shock syndrome. 5, 28 In general, use of the contraceptive sponge should be avoided until 6 weeks postpartum; it is important to counsel women that the sponge has much higher failure rates among parous women even during perfect use. 29 However, these methods are not always available as the sponge has been intermittently off the market, not all pharmacies keep these items in stock, and a major manufacturer of diaphragms in the United States recently discontinued producing them.
INTRAUTERINE CONTRACEPTION
Postplacental intrauterine device (IUD) insertion (within 10 min of placental delivery) is a convenient option for women with no contraindication to use of an IUD. Immediate postpartum insertion particularly benefits those patients who do not have other options for effective contraception, are unable or unwilling to return for later insertion or who will have difficulty obtaining an IUD at their postpartum visit. 30 Barriers to IUD provision in the postpartum period (when not provided at the time of delivery) include provider advice against the IUD, patient failure to return for a postpartum visit, and early repeat pregnancy. 30 A barrier to immediate postpartum placement is lack of reimbursement due to the global fee.
The most widely studied type of IUD for postplacental insertion is the Copper T 380A. Insertion immediately following delivery is not associated with an increased risk of infection, uterine perforation, postpartum bleeding, or uterine subinvolution. 31, 32 Although increasing in use, there are less data to date on the use of levonorgestrel-releasing IUDs immediately postpartum; however, these data demonstrate feasibility, acceptability, and effectiveness of this approach. [33] [34] [35] [36] [37] [38] The World Health Organization (WHO) and Centers for Disease Control (CDC) both support the use of levonorgestrel-releasing IUDs in postpartum women. 12, 39 An IUD may be safely placed after vaginal or cesarean delivery. 31, 34, 36, 40, 41 The main disadvantage to immediate postpartum provision is the higher expulsion rate, ranging from 8% to 51% in various studies, [33] [34] [35] [36] [37] [38] 41, 42 which must be balanced against the advantages of immediate, highly effective, and long-acting contraceptive coverage. A number of studies have reported that immediate IUD insertion within 10 minutes of placental delivery results in a significantly lower expulsion rate than insertion hours after placental delivery (delayed postpartum insertion); however, this lower rate still remains higher than the expulsion rates for interval placement (at >4 wk postpartum). 34 In 1 study, a pooled analysis of data from 9 sites worldwide found the 6-month expulsion rate for immediate IUD insertion (within 10 min of placental delivery) was 9.5% compared with 29% to 37% when insertion was performed 2 to 72 hours after placental delivery. 43 Other studies have reported similar findings; however, comparisons are challenging as the expulsion rates vary among studies due to other factors including patient age, parity, provider experience, and length of follow-up. 36, 37 Delivery type may also affect expulsion rates. In some studies, immediate insertion following cesarean delivery demonstrated lower expulsion rates than immediate insertion following vaginal delivery. 34 To date, the only randomized trial to compare immediate (within 10 min of placental delivery) versus interval insertion (6 to 8 wk postpartum) of the levonorgestrel-releasing IUD following vaginal delivery found expulsion rates of 24% and 4.4%, respectively (P = 0.008). 35 Consistent data indicate that interval insertion (at least 4 wk
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Sober and Schreiber www.clinicalobgyn.com postdelivery) provides the lowest expulsion rates. 34 One study comparing 3 timepoints-immediate postplacental, early postpartum (10 min to 72 h), and interval ( >6 wk)-found 12-month expulsion rates were 14.3%, 18.6%, and 3.8%, respectively. 44 However, even when these expulsion rates are taken into account, given the patent-level and systems barriers to traditional postpartum insertion, at least as many, if not more women will have an IUD in place at 12 months if the insertion is performed postplacentally. 37 Regardless of the timing of insertion, rates of adverse effects including pain, bleeding, infection, and perforation were similar and low. 34, 36 
PROGESTIN-ONLY CONTRACEPTIVES (PILLS, INJECTIONS, IMPLANTS)
Progestin-only contraceptives have minimal effects on coagulation factors, blood pressure, or lipid levels. 45 Large epidemiologic studies have not identified an increased risk of stroke, myocardial infarction, or VTE with their use. 45 Progestin-only contraceptives represent an appropriate contraceptive choice for postpartum women who have no contraindications to their use. Progestin-only methods can thus be initiated immediately postpartum in nonbreastfeeding women and should be initiated within 3 weeks of delivery to maximize effectiveness as ovulation can occur as early as 25 days postdelivery.
14 As with IUDs, a barrier to immediate postpartum placement of the implant is lack of reimbursement due to the global fee.
ESTROGEN-PROGESTIN CONTRACEPTIVES (PILL, PATCH, RING)
Combined hormonal contraceptives increase VTE risk 3-to 7-fold in healthy reproductive age women. [46] [47] [48] [49] As discussed previously, postpartum women have an elevated risk of VTE; this risk declines rapidly in the first 21 days postpartum and returns to baseline levels after 6 weeks postpartum.
11 Between 4 and 6 weeks postpartum, risk declined, but was still approximately 5 to 7 times that of nonpregnant, nonpostpartum women.
11
The risk of VTE must be weighed against the risk of unintended pregnancy when attempting to determine when to initiate combined hormonal contraception in the postpartum period.
As ovulation occurs 25 days after delivery at the earliest, both the WHO and CDC medical eligibility criteria (MEC) for contraceptive use recommend initiating estrogen-progestin contraceptives no earlier than 21 days postpartum. 13, 50 At that time, combined hormonal contraceptives should only be initiated in women at risk for pregnancy without additional risk factors for postpartum VTE. These risk factors include: age greater than or equal to 35 years, previous thromboembolism, thrombophilia, immobility, transfusion at delivery, body mass index Z30 kg/m 2 , postpartum hemorrhage, recent cesarean delivery, preeclampsia, or smoking. Nonbreastfeeding women with additional risk factors for postpartum VTE may initiate use of estrogen-progestin contraceptives at 6 weeks postpartum if they meet the standard criteria for use of combined hormonal contraception. 12, 39 The product labeling for estrogen-progestin contraceptives recommends waiting at least 4 weeks following delivery before initiation of these methods.
Postpartum Contraception for Breastfeeding Women
Breastfeeding is a condition for which there is no restriction on the use of nonhormonal methods, including barrier methods, Copper T 380A IUDs, and tubal sterilization. 12, 39 The use of hormonal contraception by breastfeeding women is an area of dispute among experts. As steroids pass through the breast milk to the infant, the CDC, the WHO, the
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International Planned Parenthood Federation, and the Academy for Breastfeeding Medicine do not consider hormonal contraceptive methods to be a first-line choice for breastfeeding women.
12,25,51
LACTATIONAL AMENORRHEA METHOD (LAM)
Women who breastfeed will have a delay in the resumption of ovulation due to inhibition of the pulsatile release of gonadotropin-releasing hormone from the hypothalamus by prolactin. 52 As a result, there is a decrease in estradiol levels and inhibition of ovulation. However, the degree to which ovulation is suppressed depends on a number of factors including breastfeeding patterns, biological variation, nutrition, geography, culture, and socioeconomic factors. 53, 54 Anovulation is achieved only when all of the following criteria are met: (1) breastfeeding exclusively (no supplemental feeds, also referred to as ''full breastfeeding''); (2) amenorrhea; and (3) <6 months postpartum. Given all 3 conditions, the contraceptive effect of lactational amenorrhea is 98%. [54] [55] [56] If these criteria are not met, the risk of becoming pregnant while breastfeeding is high, with 1 study reporting rates of 25%. 55, 57, 58 Approximately 70% of women remain amenorrheic through 6 months and only 37% remain amenorrheic through 1 year with full or nearly full breastfeeding; nevertheless, with exclusive breastfeeding, the contraceptive efficacy at 1 year is high, approximately 92%. 54 Supplemental feeding increases the chance of ovulation, and thus, pregnancy, even in amenorrheic women, as half of women who are not fully breastfeeding ovulate before the sixth week. 59 Lactation thus provides a contraceptive effect, but it is variable and not reliable for every woman; additional contraception is necessary during lactation for most women. Fortunately, most contraceptive methods are compatible with breastfeeding, and the provider can play an important role in promoting both contraception and breastfeeding. It is useful and acceptable to many women to have a back-up method available when any of the LAM criteria no longer apply. 29 
STERILIZATION
Tubal ligation can be performed immediately postpartum, although it can disrupt lactation if it requires general anesthesia or separation of mother and infant. 29 Performing the procedure with regional or local anesthetic minimize these issues. 60 If tubal ligation does not occur at the time of delivery, breastfeeding should occur just before the woman receives anesthesia, and be delayed immediately after to reduce the transfer of the anesthetic agent to the infant. 61, 62 However, with rapidly metabolized anesthetic agents, as soon as the mother is awake enough to hold her baby, she may breastfeed safely. If vasectomy is chosen, a back-up method of contraception may not be necessary while awaiting confirmation of successful vasectomy if the woman is breastfeeding and meets criteria for LAM.
25,63
BARRIER METHODS
As for nonbreastfeeding women, both the male and female condom can be used as soon as coitus is resumed. Lubricated condoms or spermicides may be helpful for women experiencing vaginal dryness due to breastfeeding. 5 In animal studies, nonoxynol-9 is absorbed through the skin and secreted in breast milk. 64 The question of whether nonoxynol-9 is secreted in breast milk in humans has not been completely evaluated. Other types of barrier methods, such as the diaphragm and cervical cap, require fitting which cannot be properly performed until pregnancy-related cervical changes have resolved, generally by 6 weeks postpartum; it is not advisable to use a sponge, cap, or diaphragm while still bleeding. 5 These 768 Sober and Schreiber www.clinicalobgyn.com nonhormonal methods may be preferred by breastfeeding women as they do not have systemic effects and therefore will not interfere with lactation. The same caveat applies as above for nonbreastfeeding women regarding availability of some of these methods.
INTRAUTERINE CONTRACEPTION
Breastfeeding women may safely use either the Copper T 380A IUD or a levonorgestrel-releasing IUD.
12,39
The Copper T 380A IUD does not affect the quantity or quality of breast milk. 65 The WHO MEC suggest delaying insertion of a levonorgestrel-releasing IUD until 4 to 6 weeks postpartum in breastfeeding women due to the possibility of hormonal effects on lactation. 12 The CDC MEC, however, do not restrict the use of levonorgestrel-releasing IUDs in the immediate postpartum period in the absence of puerperal sepsis. 39 There is no direct evidence that this IUD has any effect on the quantity or quality of breast milk. One study comparing breastfeeding outcomes in women receiving the levonorgestrelreleasing IUD and the Copper T 380A did not find a negative effect of the levonorgestrel-releasing IUD on lactation; however, IUD insertions for both groups were performed 6 to 8 weeks postpartum. 66 Another study found that women randomized to immediate postpartum IUD insertion were less likely to be breastfeeding at 6 months postpartum compared with women randomized to delayed insertion. 67 Some women experience cramping when they breastfeed with an IUD in place, but the cramping does not interfere with lactation or with the effectiveness of the IUD. 29 IUD insertion is less painful in breastfeeding women, and the rates of removal for pain and/or bleeding are lower. 68, 69 A recent multinational study of over 60,000 women showed that rates of uterine perforation are increased in breastfeeding women relative to nonbreastfeeding women (relative risk = 6.1, 95% confidence interval, 3.6-10.1) for both levonorgestrel and copper IUDs; however, this increase is unlikely to be clinically significant as overall rates of perforation were low. 70 
PROGESTIN-ONLY METHODS (PILLS, INJECTIONS, IMPLANTS)
If a breastfeeding woman desires to use a hormonal contraceptive method, progestin-only methods are preferred as they do not appear to affect milk volume or composition or to cause adverse effects on the infant. [71] [72] [73] However, the timing of initiation of use remains somewhat controversial. 74 As progesterone withdrawal is likely the stimulus that initiates lactogenesis, administration of progestin-only methods shortly after delivery could theoretically inhibit or alter lactation. 75 Several studies have addressed this concern and have shown that progestin-only contraceptives do not impair lactation and may in fact increase the quality and duration of lactation. [76] [77] [78] [79] Additional theoretical concerns involved the possible accumulation of progesterone and its metabolites in the infant due to an immature metabolism. 75 Depot medroxyprogesterone acetate (DMPA) provides the highest systemic level of progestin as compared with other progestin-only methods. There are limited studies examining administration of DMPA before hospital discharge in breastfeeding women, although existing studies have not shown detrimental effects on breastfeeding 78, [80] [81] [82] [83] or infant growth or development. 71, 72, 84 Similarly, studies of other progestin-only methods including progestin-only pills and etonogestrel-releasing implants have not found detrimental effects on infant growth or development 71, 72, [85] [86] [87] [88] or adverse impact on breastfeeding. 73, 89 Progestin-only methods may protect against the bone loss associated with lactation, a potential advantage especially in undernourished women. 90 
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The CDC MEC indicate that progestin-only methods-including progestinonly pills, DMPA injections, and etonogestrel implants-are safe for use in postpartum women, including women who are breastfeeding. 39 The CDC MEC also state that these methods can be initiated immediately postpartum. 39 In contrast, the WHO MEC recommends initiating progestin-only contraceptives 6 weeks postpartum in breastfeeding women as there are insufficient data regarding neonatal safety before then. 12 However, for patients at high risk of increased morbidity or mortality with a subsequent gestation and/or who experience difficulty accessing health care, initiation of these methods is recommended in the immediate postpartum period. 12, 91 The manufacturers' package inserts also recommend waiting until 6 weeks postpartum in women who are exclusively breastfeeding or 3 weeks postpartum in women who are supplementing with formula. Many experts recommend use of progestin-only methods immediately postpartum as they believe that the real risks of unintended pregnancy outweigh the theoretical risks to breastfeeding or the infant.
5,74
ESTROGEN-PROGESTIN CONTRACEPTIVES (PILL, PATCH, RING)
Combined hormonal contraceptives (estrogen-progestin pills, patch, ring) could theoretically suppress milk production in the early postpartum period through their effect on prolactin. Some studies present data demonstrating diminished quantity or quality of breast milk in postpartum women using combined hormonal contraceptives [92] [93] [94] [95] ; however, there is no strong evidence of a significant difference in infant outcomes due to use of combined hormonal contraception during lactation. 96 An 8-year follow-up study of children breastfed by mothers using combined oral contraceptives detected no effect on diseases, intelligence level, or psychological behavior. 94 A 2010 systematic review did not find any evidence of adverse infant health outcomes in children of women using estrogen-progestin contraceptives while breastfeeding, although 1 study demonstrated lower average infant weights during the first year of life. 97 The review was limited to 8 studies (4 randomized, 4 observational) and found the evidence overall inconsistent regarding the effect of estrogen-progestin contraceptives on breastfeeding duration and success. 97 However, 3 of the 4 randomized-controlled trials showed decreased durations of breastfeeding, 97 prompting the WHO recommendations presented below.
A subsequent randomized trial comparing women who initiated progestinonly pills versus combined hormonal contraception at 2 weeks postpartum found no difference in either breastfeeding continuation rates or infant growth parameters at 8 weeks postpartum. 98 There continued to be no difference between groups in breastfeeding continuation at 6 months postpartum; infant growth was not reassessed. 98 A prospective trial comparing initiation of estrogenprogestin contraceptives, 2 types of progestin-only contraceptives (levonorgestrel-releasing IUD and etonogestrelreleasing implant) or the Copper T 380A IUD at 6 weeks postpartum subsequently found no difference in the amount of infant milk intake and growth up to 9 weeks of age. 99 This same trial found similar incidence of full breastfeeding and breastfeeding continuation with hormonal contraceptive use and nonuse. 99 The CDC MEC recommends delaying initiation of estrogen-progestin contraceptives until at least 21 days postpartum in all women due to the increased risk of VTE, and considers the risks greater than benefits until 30 days postpartum in breastfeeding women with no additional risk factors for VTE because of possible
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Sober and Schreiber www.clinicalobgyn.com detrimental effects on milk supply. 39 In women with additional risk factors for VTE, estrogen-progestin contraceptives should not be initiated until 6 weeks postpartum as long as the woman meets standard criteria for use of combined hormonal contraception. 39 In contrast, the WHO MEC recommends delaying the initiation of estrogen-progestin contraceptives until 6 months postpartum. 12 According to the WHO MEC, between 6 weeks and 6 months, the theoretical or proven risks usually outweigh the advantages of initiating these drugs. 12 
EMERGENCY CONTRACEPTION
There is little if any published data regarding emergency contraception use during breastfeeding. 29 Given knowledge of both breastfeeding and contraception, unprotected intercourse or a contraceptive failure before postpartum day 21 does not require the use of an emergency method. 100 A Copper T 380A IUD may be inserted as emergency contraception after 4 weeks postpartum. 12, 39 According to both the WHO and CDC MEC, progestin-only pills can be used for emergency contraception without restriction by breastfeeding women. 12, 39 The safety of ulipristal acetate has not been established for breastfeeding.
Postpartum Contraception and Depression
The use of any type of contraception in women with a past or current history of depression is not restricted by either the CDC or WHO MEC. However, both MEC acknowledge that the data of the effect of these drugs on postpartum depression are limited and conflicting. 12, 39 One randomized trial assigning healthy postpartum women to receive either an injectable progestin (norethisterone enanthate) or placebo within 48 hours postpartum found higher depression scores 6 weeks postpartum in the progestin group. 101 In contrast, a retrospective study evaluating depression scores at 6 weeks postpartum among women who received DMPA in the immediate postpartum period versus controls who received no hormonal contraception found no difference between the groups. 102 Some experts caution against using DMPA immediately postpartum in women with a history of severe postpartum depression and recommend waiting until 6 weeks postpartum to administer the first injection. 103 
Adolescents
Adolescents are a particularly important population for targeted postpartum contraceptive counseling given the frequency of short-interval repeat pregnancies with at least one quarter of adolescent mothers bearing another child within 2 years. [104] [105] [106] Rapid repeat pregnancies (RRPs) both increase the risk for adverse perinatal outcomes 1, 107, 108 and negatively affect outcomes for teenage mothers. [108] [109] [110] [111] [112] [113] Prior studies demonstrate that adolescents who used either DMPA or long-acting reversible contraceptive (LARC) methods had lower rates of repeat pregnancy at 1 and 2 years postpartum. 106, [114] [115] [116] [117] [118] In particular, the IUD and the contraceptive implant have been proven effective in reducing RRP in this population by up to 35-fold compared with their peers using other methods or no method. [119] [120] [121] Risk of RRP is decreased when LARC methods are initiated earlier within the postpartum period. 122 
Conclusions
Given the importance of healthy pregnancy spacing, the immediate postpartum period provides a window of opportunity for appropriate family planning in a population, especially as women are Postpartum Contraception 771 motivated to avoid a subsequent pregnancy in the near future. Recent pregnancy and a new infant provide strong motivation for the mother to consider using contraception. The potential risk of pregnancy soon after delivery underscores the importance of initiating postpartum contraception in a timely manner. When electing a contraceptive method, informed choice is paramount. The availability of LARC methods immediately postpartum provides a strategy to achieve reductions in unintended pregnancy.
